ArticleAging2022

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types.

Jia-Zheng Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.